JNC – 8 Jim Hoehns, Pharm.D .
description
Transcript of JNC – 8 Jim Hoehns, Pharm.D .
![Page 1: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/1.jpg)
JNC – 8
Jim Hoehns, Pharm.D.
![Page 2: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/2.jpg)
Evidence Review Randomized controlled trials Adults ≥ 18 years old with hypertension N >100 Duration: ≥ 1 year Outcomes
Mortality, CVD related-mortality, CKD-related mortality MI, HF, hospitalization-HF Coronary or other revascularization ESRD▪ KF resulting in dialysis or transplantation, doubling of Cr value, halving of
GFR
![Page 3: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/3.jpg)
3 Questions
In adults with HTN, Does initiating antihypertensive drug
therapy at specific BP thresholds improve health outcomes?
Does treatment with antihypertensive drug therapy to a specified goal lead to improvement in health outcomes?
Do various antihypertensive drugs or drug classes differ in comparative benefits and harms on specific health outcomes?
![Page 4: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/4.jpg)
![Page 5: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/5.jpg)
![Page 6: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/6.jpg)
![Page 7: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/7.jpg)
![Page 8: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/8.jpg)
![Page 9: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/9.jpg)
![Page 10: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/10.jpg)
![Page 11: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/11.jpg)
Question 1• 45 y.o. white female• Hx: HTN, hyperlipidemia, MDD• Meds: Atorvastatin 20mg QD, Fluoxetine 20mg QD• BP: 150/96, HR: 73Treatment:1. Lisinopril 10mg
QD2. Amlodipine 5mg3. HCTZ 12.5-25mg
QD4. Metoprolol BID
100 0 0 0
![Page 12: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/12.jpg)
Question 2•64 y.o. white male• Hx: CKD, HTN, hyperlipidemia• Meds: simvastatin 20mg QD, ASA 81mg QD, lisinopril 20mg QD• Labs: Cr = 1.9, K+ = 4.8, Est Clcr = 38 ml/min• BP: 152/94, HR: 68Treatment:1. HCTZ 12.5-25mg QD2. Amlodipine 5mg QD3. Losartan 50mg QD4. Increase lisinopril to
40mg QD 100 0 0 0
![Page 13: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/13.jpg)
Question 3•56 y.o. black male• Hx: diabetes, HTN, obstructive sleep apnea• Meds: metformin 1000mg BID, ASA 81mg QD, Gluctotrol XL 10mg QD• Labs: Cr = 1.0• BP: 148/88, HR: 70• Treatment:1. lisinopril 10mg QD2. losartan 50mg QD3. HCTZ 12.5-25mg QD4. Furosemide 20mg QD
100 0 0 0
![Page 14: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/14.jpg)
Question 4•67 y.o. white male•Hx: HTN, DM, hyperlipidemia, GERD, BPH•Meds: finasteride 5mg QD, Zocor 80mg QD, terazosin 10mg QD, glimepride 4mg QD, Actos 45mg QD, lisinopril 10mg QD, metformin XR 2000mg/d, ASA 81mg QD•Labs: Cr: 1.2, microalbumin 10mg/L, K+ = 4.3•BP: 160/88,HR: 57Treatment
1. HCTZ 12.5-25mg QD2. Hydralazine 25mg BID3. Diltiazem XR 180mg QD4. Increase lisinopril to
20mg QD 100 0 0 0
![Page 15: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/15.jpg)
Question 5•77 y.o. female•Hx: HTN, osteoporosis, angina, GERD•Meds: Reclast 5mg Qyear, Prilosec 40mg QD, Toprol XL 100mg QD, ASA, lisinopril/HCTZ 20/25mg QD•BP: 169/66, HR: 57, weight: 100 lbs, Cr = 0.3, K+ = 4.2Treatment:
1. Terazosin 2. Amlodipine 3. Hydralazine4. Furosemide 100 0 0 0
![Page 16: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/16.jpg)
Question 6•78 y.o. female•Hx: Afib (c/o palpitations), HTN•Meds: warfarin, metoprolol 100mg BID, losartan 50mg QD•BP: 154/82 HR: 90Treatment1. Amlodipine 2. Diltiazem XR 3. Spironolactone4. Furosemide 100 0 0 0
![Page 17: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/17.jpg)
Question 7•66 y.o. black male• Hx: HTN, s/p MI 2 months ago, hyperlipidemia• Meds: atorvastatin 20mg QD, ASA 81mg QD, Plavix 75mg QD, HCTZ 25mg QD, metoprolol 100mg BID• BP: 152/92, HR: 62Treatment1. Amlodipine2. Lisinopril3. Diltiazem XR4. Furosemide 100 0 0 0
![Page 18: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/18.jpg)
Question 8•66 y.o. male•Hx: CKD, HTN, diabetes, PAD, hypothyroidism, hyperlipidemia•Meds: ASA 81mg QD, Lantus + Humalog, levothyroxine 0.1mg QD, Crestor 20mg QD, lisinopril 20mg QD•Labs: Cr = 2.8, K+ = 4.8•BP: 150/92, HR: 68Treatment
1. atenolol2. amlodipine3. HCTZ4. hydralazine 100 0 0 0
![Page 19: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/19.jpg)
Question 9•70 y.o. male •Hx: HTN, LVH, GERD, TIA•Meds: Plavix 75mg QD, famotidine 20mg QD, HCTZ 25mg QD•BP: 154/86, HR: 70Treatment1. Metoprolol2. Lisinopril3. Amlodipine4. Spironolactone
100 0 0 0
![Page 20: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/20.jpg)
Question 10•62 y.o. female•Hx: COPD, HTN, OA, obesity, CAD, occ symptomatic angina•Meds: Spiriva, Advair, ASA, Imdur 90mg QD, lisinopril 40mg QD, metoprolol XL 100mg QD, Nitrostat PRN•BP: 152/90, HR: 64 Treatment
1. HCTZ2. valsartan3. amlodipine4. terazosin
100 0 0 0
![Page 21: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/21.jpg)
![Page 22: JNC – 8 Jim Hoehns, Pharm.D .](https://reader033.fdocuments.in/reader033/viewer/2022061500/56816771550346895ddc5f3a/html5/thumbnails/22.jpg)
Summary
Age ≥ 60: goal BP is <150/90 Age <60: goal BP is <140/90 First line therapies
Thiazide, CCB’s, ACEI, ARB Thiazide or CCB recommended over
ACEI in blacks with diabetes Beta-blockers: not recommended as
first line therapy